Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 6/28/17 (What's New)

Summary

  • Tenofovir AF is an alanine ester prodrug of tenofovir first approved for the treatment of HIV infection in combination with other antiretroviral agents[FDA COBI/EVG/FTC/TAF; FDA FTC TAF; FDA FTC RPV TAF; DHHS ART]
  • Tenofovir AF is characterized by reduced systemic levels of tenofovir as compared with tenofovir DF and is associated with reduced bone and renal toxicity[Ruane 2013; Sax 2015]
  • In the treatment of HBV, tenofovir AF has similar efficacy as tenofovir DF but with the improved bone and renal effects and a higher incidence of ALT normalization[Chan 2016; Buti 2016]

Action required